[1] Dimopoulos MA, Hillengass J, Usmani S, et al.Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement[J]. J Clin Oncol,2015,33(6):657-664.
[2] Mihailovic J, Goldsmith SJ.Multiple myeloma: 18F-FDG-PET/CT and diagnostic imaging[J]. Semin Nucl Med,2015,45(1):16-31.
[3] Cavo M, Terpos E, Nanni C, et al.Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group[J]. Lancet Oncol,2017,18(4):e206-e217.
[4] Regelink JC, Minnema MC, Terpos E, et al.Comparison of modern and conventional imaging techniques in establishing multiple myeloma-related bone disease: a systematic review[J]. Br J Haematol,2013,162(1):50-61.
[5] Weng WW, Dong MJ, Zhang J, et al.A systematic review of MRI, scintigraphy, FDG-PET and PET/CT for diagnosis of multiple myeloma related bone disease--which is best?[J]. Asian Pac J Cancer Prev,2014,15(22):9879-9884.
[6] van Lammeren-Venema D, Regelink JC, Riphagen II, et al. 18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systema-tic review[J]. Cancer,2012,118(8):1971-1981.
[7] Sachpekidis C, Mai EK, Goldschmidt H, et al.(18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate[J]. Clin Nucl Med,2015,40(6):e300-e307.
[8] Salaun PY, Gastinne T, Frampas E, et al.FDG-positrone-mission tomography for staging and therapeutic assessment in patients with plasmacytoma[J]. Haematologica,2008,93(8):1269-1271.
[9] Zamagni E, Patriarca F, Nanni C, et al.Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation[J]. Blood,2011,118(23):5989-5995.
[10] Patriarca F, Carobolante F, Zamagni E, et al.The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation[J]. Biol Blood Marrow Transplant,2015,21(6):1068-1073.
[11] Bartel TB, Haessler J, Brown TL, et al.F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma[J]. Blood,2009,114(10):2068-2076.
[12] Nanni C, Zamagni E, Celli M, et al.The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients[J]. Clin Nucl Med,2013,38(2):e74-e79.
[13] Usmani SZ, Mitchell A, Waheed S, et al.Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3[J]. Blood,2013,121(10):1819-1823.
[14] Fonti R, Larobina M, Del Vecchio S, et al.Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma[J]. J Nucl Med,2012,53(12):1829-1835.
[15] Zamagni E, Nanni C, Gay F, et al.18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease[J]. Leukemia,2016, 30(2):417-422.
[16] Mateos MV, Hernández MT, Giraldo P, et al.Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial[J]. Lancet Oncol,2016,17(8):1127-1136.
[17] Albano D, Bosio G, Treglia G, et al. 18F-FDG PET/CT in solitary plasmacytoma: metabolic behavior and progression to multiple myeloma[J/OL]. Eur J Nucl Med Mol Imaging.2017-08-19[2017-10-25]. https://www.ncbi.nlm.nih.gov/pubmed/28822997.
[18] Lapa C, Knop S, Schreder M, et al.11C-Methionine-PET in Multiple Myeloma: Correlation with Clinical Parameters and Bone Marrow Involvement[J]. Theranostics,2016, 6(2):254-261.
[19] Lin C, Ho CL, Ng SH, et al.(11)C-acetate as a new biomarker for PET/CT in patients with multiple myeloma: initial staging and postinduction response assessment[J]. Eur J Nucl Med Mol Imaging,2014,41(1):41-49.
[20] Nanni C, Zamagni E, Cavo M, et al.11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma[J]. World J Surg Oncol,2007,5:68.
[21] Wester HJ, Keller U, Schottelius M, et al.Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging[J]. Theranostics,2015,5(6):618-630.
[22] Herrmann K, Schottelius M, Lapa C, et al.First-in-human experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease[J]. J Nucl Med,2016,57(2):248-251. |
